Orchestra Biomed Holdings, Inc. (HSAQ) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CareDx, Inc.

Tactile Systems Technology, Inc.

Surmodics, Inc.

Pulmonx Corp.

CVRx, Inc.

AirSculpt Technologies, Inc.

Organogenesis Holdings, Inc.

Orchestra Biomed Holdings, Inc.

Utah Medical Products, Inc.

Nano-X Imaging Ltd.

OraSure Technologies, Inc.

Why is Orchestra Biomed Holdings, Inc. ?

Flat results in Mar 26

INTEREST(9M) At USD 2.1 MM has Grown at inf%
OPERATING CASH FLOW(Y) Lowest at USD -54.52 MM
PRE-TAX PROFIT(Q) At USD -20.66 MM has Fallen at -56.03%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 33.44%, its profits have risen by 13.1%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Orchestra Biomed Holdings, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Orchestra Biomed Holdings, Inc.

33.44%

-0.71

70.76%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

142.32%

EBIT Growth (5y)

-366.47%

EBIT to Interest (avg)

-36.76

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.07

Sales to Capital Employed (avg)

0.10

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

50.19%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.93

EV to EBIT

-3.36

EV to EBITDA

-3.39

EV to Capital Employed

-14.98

EV to Sales

5.21

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-83.55%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

NET SALES(HY)

Higher at USD 31.03 MM

NET PROFIT(HY)

Higher at USD -14.66 MM

CASH AND EQV(HY)

Highest at USD 200.91 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 378.31 times

-17What is not working for the Company

INTEREST(9M)

At USD 2.1 MM has Grown at inf%

OPERATING CASH FLOW(Y)

Lowest at USD -54.52 MM

PRE-TAX PROFIT(Q)

At USD -20.66 MM has Fallen at -56.03%

NET PROFIT(Q)

At USD -20.66 MM has Fallen at -56.03%

RAW MATERIAL COST(Y)

Grown by 81.79% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -119.23 %

OPERATING PROFIT(Q)

Lowest at USD -21.99 MM

Here's what is working for Orchestra Biomed Holdings, Inc.

Net Sales

At USD 31.03 MM has Grown at 2,667.8%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Net Sales

Higher at USD 31.03 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Cash and Eqv

Highest at USD 200.91 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio

Highest at 378.31 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Orchestra Biomed Holdings, Inc.

Interest

At USD 2.1 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

At USD -20.66 MM has Fallen at -56.03%

over average net sales of the previous four periods of USD -13.24 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -20.66 MM has Fallen at -56.03%

over average net sales of the previous four periods of USD -13.24 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -54.52 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -21.99 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Debt-Equity Ratio

Highest at -119.23 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 81.79% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales